Cancer-associated thrombosis in pediatric patients. Issue 191 (July 2020)

• Record Type: Journal Article
• Authors: Barg, Assaf Arie; Kenet, Gili
• Is Part Of: Thrombosis research. Issue 191(2020)Supplement 1
• Page Start: S22
• Page End: S25
• Publication Date: 2020-07
• Subjects: Thrombosis -- Pediatric -- Cancer -- Leukemia -- Central venous line; Thrombosis -- Periodicals; 616.135
• DOI: 10.1016/S0049-3848(20)30392-3
• Languages: English
• ISSNs: 0049-3848

Abstract

Abstract : ABSTRACT Childhood malignancy and especially acute lymphoblastic leukemia are increasingly associated with thromboembolism. The etiology of pediatric cancer associated thrombosis is multifactorial and may reflect a tumor mass effect, tumor thrombi, alterations of the hemostatic system, treatment-related hazards (e.g. procoagulant changes induced by chemotherapy), presence of central venous lines and comorbidities (e.g. inherited thrombophilia). With over 80% cure rates of childhood cancer, strategies for prevention as well as for early diagnosis and optimal treatment of thromboembolism in children with malignancies are of major importance. While the use of therapeutic low molecular weight heparin prevails, prospective studies regarding guidelines for treatment or prevention are currently lacking. This review will address the epidemiology, etiology and risk factors for thrombosis, describe the presently available evidence associated with current therapy, and offer a glimpse into future treatment options.